Shionogi & Co., Ltd. Unsponsored ADR (OTCMKTS:SGIOY – Get Free Report) posted its quarterly earnings results on Tuesday. The company reported $0.18 EPS for the quarter, topping analysts’ consensus estimates of $0.15 by $0.03, Zacks reports. The business had revenue of $881.71 million during the quarter, compared to the consensus estimate of $895.52 million. Shionogi & Co., Ltd. Unsponsored ADR had a return on equity of 13.70% and a net margin of 41.82%.
Shionogi & Co., Ltd. Unsponsored ADR Price Performance
Shares of OTCMKTS:SGIOY opened at $8.79 on Wednesday. The company has a quick ratio of 5.21, a current ratio of 5.84 and a debt-to-equity ratio of 0.01. The firm has a 50-day simple moving average of $10.51 and a 200 day simple moving average of $9.77. The company has a market cap of $14.96 billion, a PE ratio of 11.57, a P/E/G ratio of 0.75 and a beta of 0.10. Shionogi & Co., Ltd. Unsponsored ADR has a fifty-two week low of $7.38 and a fifty-two week high of $12.00.
Analyst Ratings Changes
A number of research analysts have commented on the company. Zacks Research downgraded Shionogi & Co., Ltd. Unsponsored ADR from a “hold” rating to a “strong sell” rating in a report on Thursday, April 16th. The Goldman Sachs Group raised Shionogi & Co., Ltd. Unsponsored ADR to a “hold” rating in a research report on Wednesday, April 8th. One equities research analyst has rated the stock with a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat, the company currently has an average rating of “Reduce”.
Shionogi & Co., Ltd. Unsponsored ADR Company Profile
Shionogi & Co, Ltd. is a Japan-based pharmaceutical company that conducts research, development, manufacturing and marketing of prescription drugs and vaccines. Established in the late 19th century, the company has expanded its focus beyond domestic markets to become a global player in pharmaceuticals, with particular expertise in anti-infectives, pain management, cardiovascular and central nervous system disorders.
The company’s product portfolio spans both established and innovative therapies.
Featured Stories
- Five stocks we like better than Shionogi & Co., Ltd. Unsponsored ADR
- Dream Finders Homes’ Hostile Bid Creates a Dual Squeeze Play
- Why OpenAI’s IPO Plans Could Be a Massive Win for Microsoft
- A Real Biggie Deal: Wendy’s Serves Up a Juicy Buyout Arbitrage
- Ally Financial Is Back to Basics—And Investors Are Watching
Receive News & Ratings for Shionogi & Co. Ltd. Unsponsored ADR Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Shionogi & Co. Ltd. Unsponsored ADR and related companies with MarketBeat.com's FREE daily email newsletter.
